Menu

Roanoke Revisited

In July 1587, a British colonist named John White accompanied 117 people to settle a small island sheltered within the barrier islands of what would become North Carolina’s Outer Banks. 

Jan 1, 2012
Kerry Grens

In July 1587, a British colonist named John White accompanied 117 people to settle a small island sheltered within the barrier islands of what would become North Carolina’s Outer Banks. When conditions proved harsher than anticipated, White agreed to sail back to Britain to shore up the settlement’s supplies—a trip that should have lasted a few months. When White belatedly returned in 1590, the colonists had vanished—more than 100 men, women, and young children, their shelters and belongings, all gone. Archaeological digs, weather records, historical writings, genealogy—none have fully answered the question of what happened during White’s absence. But Roberta Estes, who owns DNAeXplain, a company that interprets the results of genetic heritage tests, is looking to DNA for help. Her hypothesis is that the Lost Colonists survived, and that evidence of their salvation is tucked away in the mitochondrial or Y chromosomal DNA of living descendants.

Read the full story.[gallery]

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.